ClinicalTrials.gg
CompletedNCT06733298Updated Feb 25, 2025

A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants

A Phase 1 interventional study of [ 14C]-labeled RO7269162 in Healthy Volunteers, sponsored by Hoffmann-La Roche. Completed at 1 site in Netherlands. Open to male participants aged 35 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
35 Years to 64 Years
Sex
Male
01

Study summary

This study will investigate how RO7269162 labeled with a carbon tracer ([14C]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged 35 to 64 years of age (inclusive), at screening
  • Body weight ≥ 50 kg and within the range 18 to 30 kg/m2 (inclusive), at screening
  • Male participants who, for 3 months after dosing of [14C]-RO7269162, agree to: remain abstinent (refrain from heterosexual intercourse) or use as defined by the protocol with a partner that is a woman of ; remain abstinent or use contraception with a pregnant female partner; refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • History or evidence of any gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease, metabolic disorder, cancer, or cirrhosis
  • Any disease or condition that could interfere with the conduct of the study or pose an unacceptable risk to the participant
  • History or evidence of any medical condition that could potentially alter the absorption, metabolism, or elimination of drugs
  • Surgical history of the gastrointestinal (GI) tract affecting gastric motility or altering the GI tract (with the exception of uncomplicated appendectomy and hernia repair)
  • History of
  • Use of any prescription drugs, herbal supplements, and/or over-the-counter medication (OTC), dietary supplements (vitamins included) within 2 weeks before Day 1. Use of any prohibited food before study start and during the study as defined by the protocol
  • Likely to need medication during the study period except for those defined by the protocol
  • Are currently enrolled in, have participated in, or plan to participate in any other clinical study involving an medicinal product or medical device study from within the 30 days directly preceding screening or within 5 times the elimination half-life, if known (whichever is longer), until completion of the follow-up visit
  • Evidence of (HIV), , or
  • Donation of blood or blood products for transfusion over 100 mL or significant blood loss within 2 months prior to screening through study completion, clinic discharge or early termination, inclusive. Donation of blood or plasma is not allowed throughout the entire study. Receipt of blood products within 2 months prior to Day -1 is not allowed
  • Clinically significant history of or allergic reactions
  • Regular work with ionizing radiation or radioactive material, or exposure to ionizing radiation within 1 year prior to study drug administration
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants will receive one oral dose of \[14C\]-labeled RO7269162 on Day 1.

    Drug: [ 14C]-labeled RO7269162

Interventions

  • Drug[ 14C]-labeled RO7269162

    Participants will receive one oral dose of \[14C\]-labeled RO7269162.

06

What researchers measure

Primary outcomes

  1. [14C] recovery in urine

    Time frame: Up to Day 22 or Day 37

  2. [14C] recovery in feces

    Time frame: Up to Day 22 or Day 37

  3. Concentration of [14C] in whole blood

    Time frame: Up to Day 22 or Day 37

  4. Plasma concentration of [14C]

    Time frame: Up to Day 22 or Day 37

  5. Plasma concentration of RO7269162

    Time frame: Up to Day 22 or Day 37

  6. Amount of RO7269162 excreted in urine

    Time frame: Up to Day 22 or Day 37

Secondary outcomes

  1. Amount of RO7269162 metabolites in plasma

    Time frame: Up to Day 22 or Day 37

  2. Amount of RO7269162 metabolites in blood

    Time frame: Up to Day 22 or Day 37

  3. Amount of RO7269162 metabolites excreted in urine

    Time frame: Up to Day 22 or Day 37

  4. Amount of RO7269162 metabolites excreted in feces

    Time frame: Up to Day 22 or Day 37

  5. Incidence and severity of adverse events

    Time frame: Up to Day 22 or Day 37

07

Study locations

1 site
  • ICON Health sciences research center
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jan 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Jan 8, 2025
Primary completionActual
Jan 29, 2025
CompletionActual
Jan 29, 2025
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06733298
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jan 8, 2025
Primary completion
Jan 29, 2025
Completion
Jan 29, 2025
Last update
Feb 25, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion